Xiaobo Yang

4.4k total citations · 1 hit paper
100 papers, 2.6k citations indexed

About

Xiaobo Yang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xiaobo Yang has authored 100 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 34 papers in Surgery. Recurrent topics in Xiaobo Yang's work include Cholangiocarcinoma and Gallbladder Cancer Studies (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers) and Pancreatic and Hepatic Oncology Research (16 papers). Xiaobo Yang is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers) and Pancreatic and Hepatic Oncology Research (16 papers). Xiaobo Yang collaborates with scholars based in China, United States and United Kingdom. Xiaobo Yang's co-authors include Haitao Zhao, Xinting Sang, Jianzhen Lin, Junyu Long, Yi Bai, Anqiang Wang, Dongxu Wang, Bo Hu, Xu Yang and Xueshuai Wan and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Journal of Virology.

In The Last Decade

Xiaobo Yang

98 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

2024 43 citations Nan Zhang, Ziyu Xun et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaobo Yang China	30	1.0k	1.0k	999	727	547	100	2.6k
Yohei Masugi Japan	31	1.1k 1.1×	857 0.8×	617 0.6×	677 0.9×	554 1.0×	127	2.9k
Eric Santoni‐Rugiu Denmark	35	1.2k 1.1×	1.7k 1.7×	681 0.7×	757 1.0×	524 1.0×	108	3.3k
Ning Ren China	36	985 1.0×	1.8k 1.8×	1.5k 1.5×	594 0.8×	407 0.7×	113	3.7k
Chia-Jui Yen Taiwan	28	955 0.9×	1.1k 1.0×	613 0.6×	530 0.7×	272 0.5×	63	2.7k
Shigetoyo Saji Japan	29	1.1k 1.1×	1.0k 1.0×	480 0.5×	475 0.7×	573 1.0×	173	2.8k
Wei‐Hua Jia China	30	979 1.0×	1.4k 1.4×	1.1k 1.1×	339 0.5×	352 0.6×	104	2.8k
Naoya Ikeda Japan	27	1.6k 1.5×	768 0.8×	483 0.5×	473 0.7×	759 1.4×	93	2.9k
Wang Li China	27	543 0.5×	769 0.8×	470 0.5×	497 0.7×	313 0.6×	108	2.0k
Jeng‐Kai Jiang Taiwan	31	1.6k 1.6×	682 0.7×	568 0.6×	545 0.7×	615 1.1×	124	2.6k
Luca Faloppi Italy	25	807 0.8×	580 0.6×	601 0.6×	499 0.7×	223 0.4×	92	1.8k

Countries citing papers authored by Xiaobo Yang

Since Specialization

Citations

This map shows the geographic impact of Xiaobo Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobo Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobo Yang more than expected).

Fields of papers citing papers by Xiaobo Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobo Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobo Yang. The network helps show where Xiaobo Yang may publish in the future.

Co-authorship network of co-authors of Xiaobo Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobo Yang. A scholar is included among the top collaborators of Xiaobo Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobo Yang. Xiaobo Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qin, Wu-Ming, Xiaobo Yang, Shi Ouyang, et al.. (2025). Loss of lims1 causes aberrant cardiac remodeling and heart failure via activating gp130/Jak1/Stat3 pathway in zebrafish. Journal of genetics and genomics. 52(12). 1600–1611.

Chen, Xiangqi, Shanshan Wang, Nan Zhang, et al.. (2025). Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma. Cancer Immunology Immunotherapy. 74(11). 331–331. 1 indexed citations

Li, Xu, Jinzhang Chen, Chang Liu, et al.. (2024). Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. BMC Medicine. 22(1). 172–172. 13 indexed citations

Chao, Jiashuo, Hao Wang, Shuofeng Li, et al.. (2024). Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunology Immunotherapy. 73(12). 249–249. 3 indexed citations

Zhu, Chengpei, Shanshan Wang, Yunchao Wang, et al.. (2024). Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer. Cancer Immunology Immunotherapy. 73(12). 240–240. 1 indexed citations

Wang, Yunchao, Xiaobo Yang, Yanyu Wang, et al.. (2023). Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study. Cancer Immunology Immunotherapy. 72(7). 2197–2204. 5 indexed citations

Chao, Jiashuo, Shanshan Wang, Hao Wang, et al.. (2023). Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunology Immunotherapy. 72(11). 3717–3726. 14 indexed citations

Liang, Tianyu, et al.. (2023). Galectin-3 promotes brain injury by modulating the phenotype of microglia via binding TLR-4 after intracerebral hemorrhage. Aging. 15(17). 9041–9058. 5 indexed citations

Wang, Yanyu, Xu Yang, Junyu Long, et al.. (2023). Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World Journal of Gastroenterology. 29(10). 1614–1626. 21 indexed citations

10.

Zhang, Junwei, Xiaobo Yang, Boju Pan, et al.. (2023). Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report. World Journal of Surgical Oncology. 21(1). 108–108. 3 indexed citations

11.

Zhang, Junwei, Xiaobo Yang, Man Li, et al.. (2022). Evolution of associating liver partition and portal vein ligation for staged hepatectomy from 2012 to 2021: A bibliometric analysis. Review. International Journal of Surgery. 103. 106648–106648. 5 indexed citations

12.

Lin, Jianzhen, Songhui Zhao, Dongxu Wang, et al.. (2021). Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. Frontiers in Immunology. 12. 673248–673248. 6 indexed citations

13.

Bian, Jin‐Song, Junyu Long, Xu Yang, et al.. (2021). Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. Annals of Translational Medicine. 9(9). 765–765. 7 indexed citations

14.

Shi, Ximin, Haiqun Xing, Xiaobo Yang, et al.. (2020). Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 48(5). 1593–1603. 111 indexed citations

15.

Shi, Ximin, Haiqun Xing, Xiaobo Yang, et al.. (2020). Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. European Journal of Nuclear Medicine and Molecular Imaging. 48(1). 196–203. 96 indexed citations

16.

Lin, Jianzhen, Junping Shi, Honglin Guo, et al.. (2019). Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clinical Cancer Research. 25(15). 4701–4711. 80 indexed citations

17.

Long, Junyu, Peipei Chen, Jianzhen Lin, et al.. (2019). DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 9(24). 7251–7267. 99 indexed citations

18.

Long, Junyu, Jianzhen Lin, Anqiang Wang, et al.. (2017). PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology & Oncology. 10(1). 146–146. 84 indexed citations

19.

Yang, Zhen, Xueshuai Wan, Haohai Zhang, et al.. (2014). Evolution of the mir-181 microRNA family. Computers in Biology and Medicine. 52. 82–87. 27 indexed citations

20.

Guo, Chang-Jun, Xiaobo Yang, Yanyan Wu, et al.. (2011). Involvement of caveolin-1 in the Jak–Stat signaling pathway and infectious spleen and kidney necrosis virus infection in mandarin fish (Siniperca chuatsi). Molecular Immunology. 48(8). 992–1000. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact